Ongoing Assessments & Recent Research.
Easy access to our work
Asthma
Nov 2021Chemotherapy-Induced Neutropenia
Apr 2022COVID-19
Apr 2022Diabetes: Type 2
Jan 2022Hypertrophic Cardiomyopathy
Oct 2021Myasthenia Gravis
Sep 2021Featured News & Insights.
Learn about our latest work.
ICER Publishes Final Evidence Report and Policy Recommendations on Therapies for Myasthenia Gravis
Independent appraisal committee found the evidence is adequate to demonstrate that eculizumab and efgartigimod both provide a net health benefit when compared to conventional therapy alone.
10/20/2021ICER Publishes Evidence Report on Mavacamten for Hypertrophic Cardiomyopathy
Evidence is rated as promising but inconclusive to determine whether mavacamten provides a net health benefit for patients over the long term; using patient outcomes from short-term studies, treatment would achieve common thresholds for cost-effectiveness if priced lower than $15,000 per year.
10/07/2021ICER Releases Draft Evidence Report on Therapies for Severe Asthma
Public comment period now open until October 14, 2021; Requests to make oral comment during public meeting also being accepted.
09/16/2021The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $300 million
Engaged with over 300 patient groups and patient reps
In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model
Current
Policy Papers.
Easy access to our ongoing policy papers
Unsupported Price Increases
Out of 10 identified drugs that had substantial 2019 price increases on top of already high current spending, seven were not supported by new clinical evidence; the net price increases on these seven drugs alone cost Americans an additional $1.2 billion in annual drug spend.
Strengthening the FDA’s Accelerated Approval Pathway
This paper aims to create a clearer understanding of both the opportunities and challenges inherent in the FDA’s accelerated approval pathway (AAP), and to present an analysis of the potential risks and benefits of a range of reform options that policymakers may consider in efforts to strengthen the AAP moving forward.
Cornerstones of ‘Fair’ Drug Coverage
Informed by expert input from patient groups, clinician specialty societies, payers, and life science companies, this white paper provides recommendations for appropriate design and implementation of policies that determine patient access to prescription drugs.
Latest
Developments.
We’re hiring! Click here to see our full time job listings.
Learn more about how the patient perspective influences ICER’s work, and learn how you can be involved.
Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.